A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer

Masashi Koto, Yoshihiro Takai, Yoshihiro Ogawa, Haruo Matsushita, Ken Takeda, Chiaki Takahashi, Keith R. Britton, Kei ichi Jingu, Kenji Takai, Masatoshi Mitsuya, Kenji Nemoto, Shogo Yamada

Research output: Contribution to journalArticlepeer-review

156 Citations (Scopus)


Background and purpose: The outcome of stage I non-small cell lung cancer (NSCLC) patients treated with conventional radiotherapy is inferior to that of patients treated surgically. We aimed to evaluate the clinical outcome of stereotactic body radiotherapy (SBRT) in the treatment of stage I NSCLC. Materials and methods: We performed SBRT for 31 stage I NSCLC patients. Of these, 20 were medically inoperable, and 11 refused surgery. Nineteen tumours were T1-stage masses, and 12 tumours were T2. Median tumour size was 25 mm. SBRT was administered as 45 Gy/3 fractions; however, when the tumour was close to an organ at risk, 60 Gy/8 fractions were used. These doses were prescribed at the centre of the tumours. Results: The median duration of observation for all patients was 32 months (range, 4-87 months). In 9 of the 31 cases, local recurrence was observed. The 3-year local control rates of T1 and T2 tumours were 77.9% and 40.0%, respectively. The 3-year overall and cause-specific survival rates were 71.7% and 83.5%, respectively. Although the symptoms improved with medical treatment, 5 patients developed acute pulmonary toxicity ≥grade 2. Conclusions: SBRT is safe and effective for stage I NSCLC patients. However, a more intensive treatment regimen should be considered for T2 tumours.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalRadiotherapy and Oncology
Issue number3
Publication statusPublished - 2007 Dec


  • Non-small cell lung cancer
  • On-board imaging
  • Phase II study
  • Stage I
  • Stereotactic body radiotherapy


Dive into the research topics of 'A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this